• About Us
    • Fact Checking Policy
    • Ownership & funding information
  • Volunteer
    • Internship with The Online Citizen
  • Donation
  • Subscription
  • Letter submission
    • Submissions Policy
  • Contact Us
  • zh-hans 简体中文
  • en English
The Online Citizen Asia
  • Opinion
    • Editorial
    • Commentaries
    • Comments
  • Current Affairs
    • Malaysia
    • Indonesia
    • China
    • ASEAN
    • Asia
    • International
  • Finance
    • Economics
    • Labour
    • Property
    • Business
  • Community
    • Civil Society
    • Arts & Culture
    • Consumer Watch
    • NGO
  • Politics
    • Parliament
    • Transport
    • Education
    • Environment
    • Health
    • Housing
  • Law & Order
    • Legislation
    • Court Cases
  • Lifestyle
    • Travel
No Result
View All Result
  • Opinion
    • Editorial
    • Commentaries
    • Comments
  • Current Affairs
    • Malaysia
    • Indonesia
    • China
    • ASEAN
    • Asia
    • International
  • Finance
    • Economics
    • Labour
    • Property
    • Business
  • Community
    • Civil Society
    • Arts & Culture
    • Consumer Watch
    • NGO
  • Politics
    • Parliament
    • Transport
    • Education
    • Environment
    • Health
    • Housing
  • Law & Order
    • Legislation
    • Court Cases
  • Lifestyle
    • Travel
No Result
View All Result
The Online Citizen Asia
No Result
View All Result

Moderna vaccine 94.5% effective in second breakthrough

by The Online Citizen
30/12/2020
in Health, International
Reading Time: 2min read
4

by Issam Ahmed

US biotech firm Moderna on Monday announced its experimental vaccine against Covid-19 was 94.5 percent effective, marking a second major breakthrough in the vaccine hunt.

Moderna released early results from a clinical trial with more than 30,000 participants, after US pharmaceutical company Pfizer and its German partner BioNTech last week said their vaccine was 90 percent effective.

Both vaccine frontrunners are based on a new platform called messenger RNA, which is faster to produce than traditional vaccines and effectively turn human cells into vaccine factories.

“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stephane Bancel, Moderna’s CEO.

The company plans to submit applications for emergency approval in the US and around the world within weeks, and says it expects to have approximately 20 million doses ready to ship in the US by the end of the year.

Global infections from Covid-19 have soared past 54 million with more than 1.3 million deaths since the virus emerged in China late last year.

The Moderna vaccine, which was co-developed by the US National Institutes of Health, is given in two doses 28 days apart, and the preliminary results are based on 95 volunteers of the 30,000 who fell ill with Covid-19.

Of the 95, 90 had been in the trial’s placebo group, and five in the group that received the drug, called mRNA-1273.

‘Tremendously exciting’

There were 11 people who fell severely ill, all of whom were in the placebo group.

The vaccine was well tolerated, with the majority of side-effects classed as mild or moderate.

After the first dose, about three percent of people had injection site pain classed as severe.

Among side-effects classed as severe after the second dose, about 10 percent had fatigue, nine percent had muscle pain, five percent had joint pain or headaches, four percent had other pain and two percent had redness at the injection site.

These adverse events were “short lived,” according to a statement.

“This news from Moderna is tremendously exciting and considerably boosts optimism that we will have a choice of good vaccines in the next few months,” said Peter Openshaw, a professor of experimental medicine at Imperial College London.

Crucially, Moderna also announced that its vaccine can remain stable at standard refrigerator temperatures of 2 degrees Celsius to 8 degrees Celsius (36 degrees Fahrenheit to 46 degrees Fahrenheit) for 30 days.

The company added it could be kept in long-term storage at standard freezer temperatures of -20 degrees Celsius (-4 degrees Fahrenheit) for up to six months.

Pfizer’s vaccine, on the other hand, needs to be stored in deep-freezer conditions which could complicate supply chain logistics, particularly in less developed countries.

It is not yet clear how long lasting the protection will be from either the Moderna or Pfizer vaccines, nor how well they work for the elderly, the age-group at highest risk from Covid-19.

– AFP

Share this:

  • Twitter
  • Facebook
Source: AFP
Tags: AFPCOVID-19
Subscribe
Connect withD
Login
I allow to create an account
When you login first time using a Social Login button, we collect your account public profile information shared by Social Login provider, based on your privacy settings. We also get your email address to automatically create an account for you in our website. Once your account is created, you'll be logged-in to this account.
DisagreeAgree
Notify of
I allow to create an account
When you login first time using a Social Login button, we collect your account public profile information shared by Social Login provider, based on your privacy settings. We also get your email address to automatically create an account for you in our website. Once your account is created, you'll be logged-in to this account.
DisagreeAgree
4 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments

Recent Posts

  • Vietnam reports first virus outbreak in nearly two months
  • Epic battle over GameStop as ‘nerds’ take on Wall Street
  • MHA owes the public an explanation as to why it chose to flout the UN Convention of the Rights of the Child
  • RDU expresses grave concerns over three individuals arrested for peaceful protest against anti-LGBT discrimination outside MOE building
  • WHO team to start Wuhan virus probe under global glare
  • MOH preliminarily confirms 34 new cases of COVID-19 infection; Total tally at 59,425

Trending posts

MHA owes the public an explanation as to why it chose to flout the UN Convention of the Rights of the Child

Public member complains prices at FairPrice too high and questions its mission to serve working-class SGs

Sheng Siong being compared to NTUC FairPrice after rewarding staff with up to 16 month’s bonuses

Netizens call for “full transparency” by MOH after reports of adverse events from Pfizer-BioNTech vaccination recorded in S’pore

Chan Chun Sing says not meaningful to track growth of Singaporean core in companies

Students petition MOE to stop using device management application on students’ laptops due to privacy and security concerns

Load More
November 2020
MTWTFSS
 1
2345678
9101112131415
16171819202122
23242526272829
30 
« Oct   Dec »
  • About Us
  • Volunteer
  • Donation
  • Subscription
  • Letter submission
  • Contact Us

© 2006 - 2021 The Online Citizen

No Result
View All Result
  • Opinion
    • Editorial
    • Commentaries
    • Comments
  • Current Affairs
    • Malaysia
    • Indonesia
    • China
    • ASEAN
    • Asia
    • International
  • Finance
    • Economics
    • Labour
    • Property
    • Business
  • Community
    • Civil Society
    • Arts & Culture
    • Consumer Watch
    • NGO
  • Politics
    • Parliament
    • Transport
    • Education
    • Environment
    • Health
    • Housing
  • Law & Order
    • Legislation
    • Court Cases
  • Lifestyle
    • Travel
  • Subscribers login

© 2006 - 2021 The Online Citizen

wpDiscuz
4
0
Would love your thoughts, please comment.x
()
x
| Reply